Eupraxia PharmaceuticalsEPRX
13F holders, Q3 2025 (September 30)27holders +13
15new positions
2sold out
$5.88avg. 13F price*
At the end of Q3 2025, 27 institutions reported holding Eupraxia Pharmaceuticals Inc. (EPRX) in their 13F filings, up 13 from Q2 2025. 15 opened new positions and 2 sold out. The largest holders were Beutel, Goodman & Co Ltd. ($23.9M), Vivo Capital, LLC ($8.0M) and Balyasny Asset Management L.P. ($8.0M).
- Company
- Eupraxia Pharmaceuticals Inc.
- CUSIP
- 29842P105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 15 | $63.4M |
| Exits | 2 | $169K |
All 13F filers, Q2 2025 → Q3 2025: 10,888,537 shares bought and 45,290 shares sold, net +10,843,247 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 27 holders
| Beutel, Goodman & Co Ltd. | 0.14% | New | 4,058,899 | $23.9M |
| Vivo Capital, LLC | 0.64% | New | 1,350,000 | $8.0M |
| Balyasny Asset Management L.P. | 0.02% | New | 1,350,000 | $8.0M |
| Scotia Capital Inc. | 0.03% | Reduce -1.1% | 1,277,885 | $7.3M |
| Great Point Partners LLC | 2.96% | New | 1,200,000 | $7.1M |
| Ally Bridge Group (NY) LLC | 4.52% | New | 915,000 | $5.4M |
| Logos Global Management LP | 0.52% | New | 900,000 | $5.3M |
| Royal Bank of Canada | 0.00% | Add +0.1% | 428,804 | $2.5M |
| Velan Capital Investment Management LP | 1.95% | New | 352,000 | $2.1M |
| Affinity Asset Advisors, LLC | 0.17% | New | 300,000 | $1.8M |
| Alyeska Investment Group, L.P. | 0.00% | New | 250,000 | $1.5M |
| UBS Group AG | 0.00% | Add +155.4% | 95,756 | $565K |
| Ingalls & Snyder LLC | 0.01% | Add +58.9% | 59,100 | $349K |
| Bank of America Corp. | 0.00% | Add +262.9% | 45,577 | $269K |
| Goldman Sachs Group Inc. | 0.00% | Add +0.8% | 40,100 | $237K |
| Bank of Montreal | 0.00% | No change | 37,250 | $219K |
| Raymond James Financial Inc. | 0.00% | Add +173.3% | 33,373 | $197K |
| Guardian Partners Inc. | 0.01% | New | 24,130 | $147K |
| Acadian Asset Management LLC | 0.00% | New | 21,400 | $125K |
| JPMorgan Chase & Co. | 0.00% | Reduce -12.0% | 16,467 | $97K |
| Cibc World Market Inc. | 0.00% | No change | 15,000 | $88K |
| Integrated Wealth Concepts LLC | 0.00% | New | 12,000 | $71K |
| TCI Wealth Advisors, Inc. | 0.00% | New | 11,000 | $65K |
| TD Waterhouse Canada Inc. | 0.00% | No change | 9,600 | $56K |
| Federation des caisses Desjardins du Quebec | 0.00% | New | 9,091 | $52K |
| National Bank of Canada | 0.00% | Add +20.8% | 882 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 9 | $53 |
"% of holder's portfolio" is EPRX's weight in each manager's 13F, not the share of Eupraxia Pharmaceuticals Inc. the manager owns.